Abstract
The incretin-based therapies are represented by glucagon-like peptide 1 receptor agonists (GLP-1 RA) and dipeptidyl peptidase-IV inhibitors (DPP-IV). These new therapies have revolutionized the treatment of T2DM, intervening in a pathophysiological pathway not previously addressed. This chapter will review pathophysiology, mechanism of action, and indications for the use of GLP-1 RA.
Author supplied keywords
Cite
CITATION STYLE
Bandeira, F., Moura, F., Costi, B. B., & Cardoso, A. C. S. M. (2022). GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes. In Endocrinology and Diabetes: A Problem Oriented Approach: Second Edition (pp. 335–343). Springer International Publishing. https://doi.org/10.1007/978-3-030-90684-9_31
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
